Oncternal Therapeutics SARD Ligands Cancer Treatment Patent Published
Summary
European Patent Application EP3793541A1 was published by the European Patent Office on April 15, 2026, covering selective androgen receptor degrader (SARD) ligand compounds and methods of use for cancer treatment. The patent application names Oncternal Therapeutics, Inc. and the University of Tennessee Research Foundation as applicants, with five named inventors. The designated states cover all EPC contracting states including AT, BE, DE, FR, GB, IT, NL, ES, SE, and 21 others.
About this source
GovPing monitors EPO Patent Bulletin - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 36 changes logged to date.
What changed
The European Patent Office published EP3793541A1, a European patent application for selective androgen receptor degrader (SARD) ligands and their use in treating cancer, particularly cancer types responsive to androgen receptor modulation. The application includes comprehensive IPC classifications spanning heterocyclic compounds (C07D series), pharmaceutical compositions (A61K), and therapeutic uses (A61P 35/00 for cancers including metastasis). Designated states cover all European Patent Convention contracting states.
For pharmaceutical companies and biotechnology firms developing androgen receptor-targeting therapies, this publication represents potential future competitive IP landscape implications. Any entity developing SARD compounds for cancer applications should review freedom-to-operate positions relative to the claimed molecular structures and methods disclosed in this application.
Archived snapshot
Apr 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF
Publication EP3793541A1 Kind: A1 Apr 15, 2026
Applicants
Oncternal Therapeutics, Inc., University of Tennessee Research Foundation
Inventors
NARAYANAN, Ramesh, MILLER, Duane, D., PONNUSAMY, Thamarai, HWANG, Dong-Jin, HE, Yali
IPC Classifications
C07D 231/16 20060101AFI20220125BHEP A61K 31/277 20060101ALI20220125BHEP A61K 31/167 20060101ALI20220125BHEP A61K 31/404 20060101ALI20220125BHEP A61P 35/00 20060101ALI20220125BHEP A61P 35/04 20060101ALI20220125BHEP C07C 255/60 20060101ALI20220125BHEP C07D 209/08 20060101ALI20220125BHEP C07D 209/30 20060101ALI20220125BHEP C07D 213/84 20060101ALI20220125BHEP C07D 231/12 20060101ALI20220125BHEP C07D 231/14 20060101ALI20220125BHEP C07D 231/18 20060101ALI20220125BHEP C07D 249/06 20060101ALI20220125BHEP C07D 249/18 20060101ALI20220125BHEP C07D 257/04 20060101ALI20220125BHEP C07D 303/46 20060101ALI20220125BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for EPO Patent Bulletin - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.